Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Feb;59(2):236–242. doi: 10.1038/bjc.1989.48

Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis.

R N Hitchins 1, E S Newlands 1, D B Smith 1, R H Begent 1, G J Rustin 1, K D Bagshawe 1
PMCID: PMC2247005  PMID: 2467682

Abstract

We analysed outcome in 206 consecutive male patients treated for metastatic non-seminomatous germ cell tumour (NSGCT) of testicular or extragonadal origin treated with the POMB/ACE (cisplatin, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide, etoposide) regimen after division into prognostic groups by commonly used clinical classification systems and definitions of adverse prognosis. The adverse prognostic groups of all classification systems and definitions examined showed similar, but only moderate, sensitivity (71-81%) and specificity (52-56%) in predicting death. A simple definition of poor prognosis based on raised initial levels of serum tumour markers alpha fetoprotein (aFP) and human chorionic gonadotrophin (hCG) proved at least as useful (sensitivity 80%, specificity 55%) as other more complicated systems in predicting failure to achieve long-term survival. Comparison of survival between ultra-high dose cisplatin-based combination chemotherapy and patients treated with POMB/ACE shows no advantage from this more toxic approach. This suggests that good results in adverse prognosis patients can be achieved using conventional dose regimens administered intensively.

Full text

PDF
236

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajorin D., Katz A., Chan E., Geller N., Vogelzang N., Bosl G. J. Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. J Clin Oncol. 1988 May;6(5):786–792. doi: 10.1200/JCO.1988.6.5.786. [DOI] [PubMed] [Google Scholar]
  2. Birch R., Williams S., Cone A., Einhorn L., Roark P., Turner S., Greco F. A. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol. 1986 Mar;4(3):400–407. doi: 10.1200/JCO.1986.4.3.400. [DOI] [PubMed] [Google Scholar]
  3. Bosl G. J., Geller N. L., Cirrincione C., Vogelzang N. J., Kennedy B. J., Whitmore W. F., Jr, Vugrin D., Scher H., Nisselbaum J., Golbey R. B. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res. 1983 Jul;43(7):3403–3407. [PubMed] [Google Scholar]
  4. Bosl G. J., Gluckman R., Geller N. L., Golbey R. B., Whitmore W. F., Jr, Herr H., Sogani P., Morse M., Martini N., Bains M. VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol. 1986 Oct;4(10):1493–1499. doi: 10.1200/JCO.1986.4.10.1493. [DOI] [PubMed] [Google Scholar]
  5. Daugaard G., Rŗth M. High-dose cisplatin and VP-16 with bleomycin, in the management of advanced metastatic germ cell tumors. Eur J Cancer Clin Oncol. 1986 Apr;22(4):477–485. doi: 10.1016/0277-5379(86)90115-x. [DOI] [PubMed] [Google Scholar]
  6. Einhorn L. H. Have new aggressive chemotherapy regimens improved results in advanced germ cell tumors? Eur J Cancer Clin Oncol. 1986 Nov;22(11):1289–1293. doi: 10.1016/0277-5379(86)90135-5. [DOI] [PubMed] [Google Scholar]
  7. Germa-Lluch J. R., Begent R. H., Bagshawe K. D. Tumour-marker levels and prognosis in malignant teratoma of the testis. Br J Cancer. 1980 Dec;42(6):850–855. doi: 10.1038/bjc.1980.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Logothetis C. J., Samuels M. L., Selig D. E., Ogden S., Dexeus F., Swanson D., Johnson D., von Eschenbach A. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. Am J Med. 1986 Aug;81(2):219–228. doi: 10.1016/0002-9343(86)90255-x. [DOI] [PubMed] [Google Scholar]
  9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  10. Newlands E. S., Bagshawe K. D., Begent R. H., Rustin G. J., Crawford S. M., Holden L. Current optimum management of anaplastic germ cell tumours of the testis and other sites. Br J Urol. 1986 Jun;58(3):307–314. doi: 10.1111/j.1464-410x.1986.tb09061.x. [DOI] [PubMed] [Google Scholar]
  11. Ozols R. F. Treatment of poor prognosis germ cell tumours with high dose cisplatin regimens. Int J Androl. 1987 Feb;10(1):291–300. doi: 10.1111/j.1365-2605.1987.tb00196.x. [DOI] [PubMed] [Google Scholar]
  12. Pizzocaro G., Piva L., Salvioni R., Zanoni F., Milani A. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer. Cancer. 1985 Nov 15;56(10):2411–2415. doi: 10.1002/1097-0142(19851115)56:10<2411::aid-cncr2820561012>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  13. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours. Lancet. 1985 Jan 5;1(8419):8–11. [PubMed] [Google Scholar]
  14. Samson M. K., Rivkin S. E., Jones S. E., Costanzi J. J., LoBuglio A. F., Stephens R. L., Gehan E. A., Cummings G. D. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer. 1984 Mar 1;53(5):1029–1035. doi: 10.1002/1097-0142(19840301)53:5<1029::aid-cncr2820530503>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  15. Schmoll H. J., Schubert I., Arnold H., Dölken G., Hecht T., Bergmann L., Illiger J., Fink U., Preiss J., Pfreundschuh M. Disseminated testicular cancer with bulky disease: results of a phase-II study with cisplatin ultra high dose/VP-16/bleomycin. Int J Androl. 1987 Feb;10(1):311–317. doi: 10.1111/j.1365-2605.1987.tb00198.x. [DOI] [PubMed] [Google Scholar]
  16. Stoter G., Sylvester R., Sleijfer D. T., ten Bokkel Huinink W. W., Kaye S. B., Jones W. G., van Oosterom A. T., Vendrik C. P., Spaander P., de Pauw M. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. Cancer Res. 1987 May 15;47(10):2714–2718. [PubMed] [Google Scholar]
  17. Vugrin D., Friedman A., Whitmore W. F., Jr Correlation of serum tumor markers in advanced germ cell tumors with responses to chemotherapy and surgery. Cancer. 1984 Mar 15;53(6):1440–1445. doi: 10.1002/1097-0142(19840315)53:6<1440::aid-cncr2820530637>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  18. Williams S. D., Birch R., Einhorn L. H., Irwin L., Greco F. A., Loehrer P. J. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987 Jun 4;316(23):1435–1440. doi: 10.1056/NEJM198706043162302. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES